Alprostadil (Caverject/MUSE): What People Actually Pay

Retail Pricing for Caverject and MUSE in 2025-2026

A single box of Caverject Impulse (20 mcg, six prefilled syringes) lists between $400 and $700 at major chain pharmacies, though GoodRx coupons can pull the price to roughly $250 at Costco or select independents. MUSE (medicated urethral system for erection) carries an even steeper list price. Six 1 to 000 mcg suppositories range from $500 to $900 depending on the pharmacy.

These prices reflect branded products from Pfizer (Caverject) and Meda Pharmaceuticals (MUSE). Generic alprostadil for injection exists but availability fluctuates. The FDA-approved labeling for alprostadil intracavernosal injection established efficacy at doses between 5 and 40 mcg, meaning patients who require higher doses burn through supplies faster and pay proportionally more.

Per-dose math matters here. A patient using 20 mcg Caverject twice weekly at retail pricing spends $130 to $230 per month for branded product. That same frequency with MUSE at 500 mcg costs $170 to $300 monthly. These numbers assume no insurance reimbursement. A Reddit user on r/erectiledysfunction summarized it bluntly: "I was paying $85 per shot before I found a compounding pharmacy. That's not sustainable for most guys."

Pharmacy benefit managers classify alprostadil as a specialty drug in many formularies, which triggers higher copay tiers even when the drug is covered. The American Urological Association guidelines on erectile dysfunction list intracavernosal injection as a second-line therapy after oral PDE5 inhibitors, and most insurers follow that hierarchy for coverage decisions.

Compounded Alprostadil: The Budget Alternative

Compounding pharmacies have become the primary cost-relief pathway for alprostadil users. A multi-dose vial of compounded alprostadil (typically 500 mcg/mL in a 5 mL vial) costs $60 to $150 and lasts most patients four to eight weeks depending on dose.

This pricing represents a 70% to 85% reduction compared to branded Caverject. The trade-off is that compounded preparations are not FDA-approved finished products; they are mixed per prescription under state pharmacy board oversight and, in some cases, under FDA Section 503B outsourcing facility regulations. Patients on forums frequently recommend verifying that a compounding pharmacy holds 503B registration or PCAB accreditation.

Trimix (alprostadil + papaverine + phentolamine) is the most commonly compounded combination. It typically costs $80 to $200 per multi-dose vial and offers a lower per-injection alprostadil dose, which may reduce penile pain. Dr. Irwin Goldstein, Director of San Diego Sexual Medicine, has stated: "Trimix allows us to use lower concentrations of each component, reducing side effects while maintaining the vasoactive response."

A compounded Trimix vial at 30/1/0.1 mg/mL concentration provides roughly 15 to 30 injections, bringing the per-use cost to $3 to $13. Compare that to $40 to $115 per use for branded Caverject. The economic case is not subtle.

One caution: compounded alprostadil requires refrigeration and has a shorter shelf life (typically 30 to 90 days versus the longer stability window of sealed branded kits). Patients who use the medication infrequently may waste portions of a multi-dose vial, narrowing the cost advantage.

Insurance Coverage Patterns

Coverage for alprostadil splits into three broad categories. Commercial plans with prescription drug benefits generally cover Caverject or MUSE after documented PDE5 inhibitor failure, but require prior authorization. The VA healthcare system covers alprostadil injections for service-connected conditions with minimal copay. Medicare Part D plans vary widely, with many placing alprostadil on Tier 3 or specialty tiers with 25% to 33% coinsurance after the deductible.

The prior authorization process itself creates friction. Insurers typically require documentation of failure on at least two PDE5 inhibitors (sildenafil plus tadalafil is the usual pair) and sometimes a trial of a vacuum erection device. A 2018 retrospective published in the Journal of Sexual Medicine found that 43% of men with refractory ED who were prescribed intracavernosal injections faced initial claim denials, though 71% of appeals were eventually approved.

Forum users describe the authorization timeline as "three to six weeks of phone tag." Multiple Reddit threads document cases where insurers approved the drug but limited quantity to four injections per month, forcing patients who want more frequent use to pay out of pocket for additional doses.

Manufacturer copay cards exist for Caverject but typically cap savings at $100 to $150 per fill and exclude government-insured patients. Pfizer's patient assistance program covers Caverject for uninsured patients below 200% of the federal poverty level, but the application process takes four to six weeks according to user reports.

What Clinical Trials Show About Efficacy

The key trial by Linet and Ogrinc, published in the New England Journal of Medicine in 1996 (N=296), found that intracavernosal alprostadil produced erections sufficient for intercourse in 87% of patients across a range of ED etiologies. The mean duration of erection was 31.4 minutes at a dose of 20 mcg.

For the subset most relevant to current prescribing patterns, men who had already failed oral therapy, response rates hover around 70%. This figure comes from pooled post-marketing analyses and aligns with the AUA guideline statement that intracavernosal injection therapy produces "adequate erections in approximately 70% to 90% of patients depending on ED etiology."

MUSE has a lower efficacy profile. The key MUSE trial (N=1,511) reported that 65.9% of administrations resulted in erections sufficient for intercourse in the clinic, but at-home success rates dropped to approximately 50%. The discrepancy likely reflects the learning curve for proper intraurethral insertion and the less reliable absorption compared to direct injection.

Penile pain is the most common adverse effect. In the Linet trial, 37% of patients reported penile pain, though only 5% rated it severe enough to discontinue [1]. Prolonged erection (over four hours) occurred in 5% of patients during dose titration but dropped below 1% during the maintenance phase. These numbers are important context for patient reviews, since pain complaints dominate online discussions.

Reddit and Forum Reviews: What Patients Report

Patient sentiment on alprostadil clusters into predictable themes. Efficacy reviews are overwhelmingly positive among men who have exhausted oral options.

On r/erectiledysfunction and r/Testosterone, the consensus language is some variation of "it works when nothing else does." One highly upvoted post reads: "Failed sildenafil, tadalafil, even high-dose tadalafil daily. First Trimix injection and I had the best erection in five years. The needle is nothing." Drugs.com user reviews for Caverject average 7.8 out of 10 across 89 ratings, with 68% of reviewers rating it 7 or higher.

Cost is the dominant negative theme. The phrase "insurance nightmare" appears repeatedly. A Drugs.com reviewer wrote: "Works great, 9/10 for effectiveness, but at $600 for six shots with my insurance refusing to cover it, I had to switch to compounded Trimix." Selection bias applies here: patients motivated enough to post reviews tend toward strong positive or strong negative experiences.

Pain tolerance splits the user base. Roughly a third of forum reviewers describe injection discomfort as "barely noticeable" or "less than a blood draw," while another third calls it "moderate but worth it." The remaining third reports enough pain to explore alternatives like MUSE or penile implant surgery. A recurring recommendation on Reddit is to use 30-gauge or 31-gauge needles and to inject slowly over 10 to 15 seconds. Multiple users credit this technique adjustment with reducing pain from a 6/10 to a 2/10.

MUSE receives more mixed feedback. Convenience is praised, but inconsistent results are a frequent complaint. "Works maybe half the time. When it works, it's great. When it doesn't, you just wasted $80," one r/erectiledysfunction user posted. The lower at-home response rate documented in clinical trials aligns with this anecdotal pattern.

Sample sizes on these forums are small. The largest Reddit threads contain 30 to 80 comments, and Drugs.com hosts under 100 alprostadil reviews. Self-selection bias is significant: men for whom the drug works well and who find affordable access may stop posting, while those struggling with cost or side effects remain vocal.

Cost-Saving Strategies That Patients Use

Forum discussions surface several consistent tactics. Ordering from 503B compounding pharmacies tops the list, with Help Pharmacy, Olympia Pharmacy, and Pavilion Compounding frequently named. Prices at these facilities range from $50 to $150 per vial for alprostadil mono or Trimix.

Dose optimization is the second strategy. Men who respond to lower doses (5 to 10 mcg rather than 20 to 40 mcg) get more injections per branded kit, effectively halving the per-use cost. The dose-response data from the original Linet study supports this approach: 73% of men achieved adequate erections at the 10 mcg dose, suggesting that many patients are overtreated at higher doses.

GoodRx and RxSaver coupons provide 15% to 40% savings at retail pharmacies. Costco pharmacy consistently prices Caverject lower than CVS, Walgreens, or Rite Aid based on user reports and GoodRx data. Mark Cuban's Cost Plus Drugs does not currently carry branded Caverject but does list alprostadil powder for compounding use.

Buying in larger quantities (if the prescription allows) reduces the per-unit cost. Some urologists write prescriptions for three-month supplies, which pharmacies may discount by 5% to 10%. A few users report success negotiating cash-pay pricing directly with independent pharmacies, particularly in competitive markets.

Canadian pharmacy imports are discussed on forums but carry legal and safety considerations. Personal importation of a 90-day supply for personal use falls into a gray area under FDA enforcement discretion, and product authenticity verification is limited.

MUSE vs. Caverject: Cost and Efficacy Comparison

MUSE costs more per effective dose than Caverject when you adjust for its lower success rate. At retail pricing, MUSE runs $60 to $150 per suppository. If at-home efficacy is approximately 50% (per the key trial data), the effective cost per successful erection doubles to $120 to $300.

Caverject at retail runs $40 to $115 per injection with an 87% success rate, yielding an effective cost per successful erection of $46 to $132. The injection route wins on both raw cost and cost-effectiveness.

MUSE does carry advantages for needle-averse patients. No injection technique is required, and the risk of penile fibrosis from repeated needle insertion does not apply. Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has noted: "MUSE remains a viable option for patients who cannot tolerate self-injection, provided they accept the lower response rate and higher per-dose cost."

For patients considering either option, most urologists recommend a supervised trial of intracavernosal injection first, reserving MUSE for those who decline or cannot perform self-injection. A Cochrane review of treatments for erectile dysfunction confirms this ordering, ranking intracavernosal alprostadil above intraurethral delivery for both efficacy and patient satisfaction.

When to Consider Alprostadil Over Other Options

Alprostadil occupies a specific niche: second-line therapy after PDE5 inhibitor failure and before surgical implant. The typical patient profile includes men with diabetes-related ED (response rates to PDE5 inhibitors drop to 44% to 56% in this population per a meta-analysis in Diabetes Care), post-prostatectomy ED, or vascular ED unresponsive to oral agents.

The cost calculus changes when you factor in that these men have already spent $30 to $600 monthly on PDE5 inhibitors that are not working. Switching to compounded Trimix at $5 to $13 per effective dose may actually reduce total ED treatment spending.

Penile prosthesis surgery ($15,000 to $25,000 out of pocket, often covered by insurance) provides a permanent solution but is irreversible. Alprostadil serves as a long-term bridge for men who want reliable erections without surgery, or a trial period to confirm that restored erectile function improves quality of life before committing to an implant.

Patients on nitrate medications (nitroglycerin, isosorbide) who cannot use PDE5 inhibitors represent another key population. Alprostadil has no systemic cardiovascular interaction at intracavernosal doses, making it the only pharmacologic ED option for these men according to the AUA/SMSNA guidelines.